S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:FBIO

Fortress Biotech Stock Forecast, Price & News

$2.42
-0.23 (-8.68%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.40
$2.71
50-Day Range
$2.42
$3.65
52-Week Range
$2.36
$6.10
Volume
935,441 shs
Average Volume
372,867 shs
Market Capitalization
$241.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.34
30 days | 90 days | 365 days | Advanced Chart
Receive FBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.


Fortress Biotech logo

About Fortress Biotech

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the following Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded on June 28, 2006 and is headquartered in New York, NY.

Headlines

Fortress Biotech (NASDAQ:FBIO) Earns Buy Rating from B. Riley
November 19, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FBIO
CUSIP
21976U10
Employees
111
Year Founded
N/A

Sales & Book Value

Annual Sales
$45.60 million
Book Value
$2.13 per share

Profitability

Net Income
$-46.53 million
Pretax Margin
-181.55%

Debt

Price-To-Earnings

Miscellaneous

Free Float
73,427,000
Market Cap
$241.10 million
Optionable
Optionable

Company Calendar

Last Earnings
11/15/2021
Today
12/05/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/30/2022

MarketRank

Overall MarketRank

2.09 out of 5 stars

Medical Sector

528th out of 1,388 stocks

Pharmaceutical Preparations Industry

247th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions

Is Fortress Biotech a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fortress Biotech stock.
View analyst ratings for Fortress Biotech
or view top-rated stocks.

How has Fortress Biotech's stock been impacted by COVID-19?

Fortress Biotech's stock was trading at $1.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, FBIO shares have increased by 50.3% and is now trading at $2.42.
View which stocks have been most impacted by COVID-19
.

When is Fortress Biotech's next earnings date?

Fortress Biotech is scheduled to release its next quarterly earnings announcement on Wednesday, March 30th 2022.
View our earnings forecast for Fortress Biotech
.

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) released its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.06. The biopharmaceutical company earned $21.09 million during the quarter, compared to analyst estimates of $18.41 million. Fortress Biotech had a negative trailing twelve-month return on equity of 17.04% and a negative net margin of 59.81%.
View Fortress Biotech's earnings history
.

What price target have analysts set for FBIO?

5 brokerages have issued 1 year price targets for Fortress Biotech's shares. Their forecasts range from $5.00 to $21.00. On average, they expect Fortress Biotech's stock price to reach $11.00 in the next year. This suggests a possible upside of 354.5% from the stock's current price.
View analysts' price targets for Fortress Biotech
or view top-rated stocks among Wall Street analysts.

Who are Fortress Biotech's key executives?

Fortress Biotech's management team includes the following people:
  • Lindsay Allan Rosenwald, Chairman, President & Chief Executive Officer
  • Robyn M. Hunter, Chief Financial Officer, Secretary & Treasurer
  • George C. Avgerinos, Senior Vice President-Biologics Operations
  • Michael Sean Weiss, Director & Vice Chairman-Strategic Development
  • Brian Achenbach, Vice President-Finance & Controller

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Who are Fortress Biotech's major shareholders?

Fortress Biotech's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.61%), Opaleye Management Inc. (3.71%), Geode Capital Management LLC (1.35%), Shikiar Asset Management Inc. (0.69%), Cpwm LLC (0.51%) and Morgan Stanley (0.28%). Company insiders that own Fortress Biotech stock include Eric K Rowinsky, Lindsay A Md Rosenwald, Malcolm Hoenlein and Robyn Hunter.
View institutional ownership trends for Fortress Biotech
.

Which major investors are selling Fortress Biotech stock?

FBIO stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Opaleye Management Inc., California State Teachers Retirement System, The Manufacturers Life Insurance Company , New York State Common Retirement Fund, Man Group plc, and BlackRock Inc..
View insider buying and selling activity for Fortress Biotech
or view top insider-selling stocks.

Which major investors are buying Fortress Biotech stock?

FBIO stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Telemetry Investments L.L.C., Geode Capital Management LLC, Goldman Sachs Group Inc., Summit Global Investments, Shikiar Asset Management Inc., GSA Capital Partners LLP, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have bought Fortress Biotech stock in the last two years include Lindsay A Md Rosenwald, and Malcolm Hoenlein.
View insider buying and selling activity for Fortress Biotech
or or view top insider-buying stocks.

How do I buy shares of Fortress Biotech?

Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $2.42.

How much money does Fortress Biotech make?

Fortress Biotech has a market capitalization of $241.10 million and generates $45.60 million in revenue each year. The biopharmaceutical company earns $-46.53 million in net income (profit) each year or ($0.47) on an earnings per share basis.

How many employees does Fortress Biotech have?

Fortress Biotech employs 111 workers across the globe.

What is Fortress Biotech's official website?

The official website for Fortress Biotech is www.fortressbiotech.com.

Where are Fortress Biotech's headquarters?

Fortress Biotech is headquartered at 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at (781) 652-4500, via email at [email protected], or via fax at 781-652-4545.


This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.